Jim Adair
About Jim Adair
Jim Adair is the Vice President of WW Oncology Commercial, Solid Tumors (Opdivo, Yervoy, and Opdualag) + Biomarkers at Bristol Myers Squibb, with extensive experience in managing global commercial strategies for oncology products.
Company
Jim Adair is currently working at Bristol Myers Squibb. He serves as the Vice President of Worldwide (WW) Oncology Commercial for Solid Tumors, focusing on products such as Opdivo, Yervoy, and Opdualag. His role also encompasses biomarkers.
Title
Jim Adair holds the position of Vice President, WW Oncology Commercial, Solid Tumors (Opdivo, Yervoy, and Opdualag) + Biomarkers at Bristol Myers Squibb.
Previous Roles
Before joining Bristol Myers Squibb, Jim Adair worked at Merck for 15 years from 2004 to 2019, where he served as the Executive Director of Corporate Strategy and Planning. He also held an MBA Summer Intern position in Managed Care Finance and US FE&A at Merck in 2003. Additionally, he worked as a Chemical Engineer at Eastman Chemical Company from 1999 to 2003. In 1998, he interned at Procter & Gamble, focusing on the Puffs Brand - New Products.
Education and Expertise
Jim Adair completed his MBA from Carnegie Mellon University's Tepper School of Business between 2001 and 2003. Prior to that, he earned his BS in Chemical Engineering from Penn State University, graduating in 1999. His educational background has provided him with a solid foundation in strategy, marketing, operations, and finance.
Oncology Commercial Strategy
Jim Adair has been leading the commercial strategy for Opdivo, Yervoy, and Opdualag at Bristol Myers Squibb since January 2019. His extensive experience in managing global commercial strategies for oncology products contributes significantly to his current role.